Introduction: BMS-986278, an oral lysophosphatidic acid receptor 1 (LPA) antagonist, has been shown to reduce the rate of decline in percent of predicted FVC (ppFVC) in patients with idiopathic pulmonary fibrosis (IPF) in a phase 2 study (NCT04308681).Aims & Objectives: To assess BMS-...
BMS-986278 A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in ... See More Phase 3 View trial Save trial Hematology Acute Myeloid Leukemia Trial Title Phase BMS-986397 Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Parti ... See Mo...
In addition to this Breakthrough Therapy Designation for PPF, the U.S. FDA has also previously granted BMS-986278 fast-track designation and orphan drug designation for the treatment of IPF. Bristol Myers Squibb is continuing the development of BMS-986278 with the globa...
BMS-986278, a second-generation LPA 1 antagonist, is currently in phase 2 development as a therapy for IPF and PF-ILD. Methods and analysis This phase 2, randomised, double-blind, placebo-controlled, parallel-group, international trial will include adults with IPF or PF-ILD. The trial will...
BMS-986278 is a novel next generation LPA1 antagonist currently in Phase I clinical trials. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and 尾-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human ...
Introduction: 18F-BMS-986327 is a PET tracer in development for use in target engagement and dose-receptor occupancy studies of LPA1 antagonists, such as BMS-986278, which is being evaluated in a Phase 2 study in lung fibrosis (NCT04308681). Here, the initial results for a phase 1 study ...
BMS-986278 is a potent small molecule LPA1 receptor antagonist being investigated for IPF. This study evaluated the safety, tolerability, and PK of oral BMS-986278 in healthy participants (ppts).Methods: IM027-009 is a phase 1, double-blind, placebo (PBO)-controlled, randomized study in ...